Patents Examined by David Romeo
  • Patent number: 9908916
    Abstract: The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-?B and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (CON), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN).
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: March 6, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee, Tae-Hoon Lee, A Reum Han
  • Patent number: 9889179
    Abstract: The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administrations every 3 weeks, 4 weeks or 5 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-adminsitration of an anti-inflammatory drug.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 13, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring
  • Patent number: 9890212
    Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 13, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 9884116
    Abstract: The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: February 6, 2018
    Inventor: Andrew B. Bush
  • Patent number: 9855368
    Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: January 2, 2018
    Assignees: The Regents of the University of California, Department of Veterans Affairs
    Inventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang, Keyvan Behnam
  • Patent number: 9850321
    Abstract: This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against intracellular components that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 26, 2017
    Inventor: Sunanda Singh
  • Patent number: 9840557
    Abstract: The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: December 12, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jamie M. Orengo, Jeanne Allinne
  • Patent number: 9834610
    Abstract: The present invention provides fusion proteins that act on the glucocorticoid-induced TNFR family-related gene (GITR) and OX40 signaling pathway. In certain aspects, the proteins of the invention are useful in modulating both regulatory T (Treg) cells and effector T (Teff) cells.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: December 5, 2017
    Assignees: Thomas Jefferson University, The Trustees of the University of Pennsylvania
    Inventor: Mark L. Tykocinski
  • Patent number: 9828424
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 9821059
    Abstract: The present invention relates to a composition for stabilizing TNF?-binding protein exhibiting physiological activity, and more specifically, to a composition for stabilizing protein including basic amino acid and sugar and/or ammonium salt, a pharmaceutical formulation including the same, and a method for stabilizing TNF?-binding protein. The formulation including basic amino acid; and sugar and/or ammonium salt according to the present invention effectively inhibits aggregation, denaturation and oxidation of TNF?-binding protein used for treating various diseases, for example, an anti-TNF-alpha antibody, such that the protein is capable of being preserved and stored for a long time, which is widely usable and effective in a medical field using TNF?-binding protein, for example, an anti-TNF-alpha antibody.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: November 21, 2017
    Assignee: ALTEOGEN INC.
    Inventors: Soon Jae Park, Hye-Shin Chung, Jin Hwan Kim, Minsoo Byun, Ji Hyeon Yeon
  • Patent number: 9822179
    Abstract: The present invention relates in general to the field of TNF ligand family members. In more detail the present invention relates to polypeptides comprising at least three components A, each of which comprises the sequence of a TNF homology domain (THD) of a TNF ligand family member, or a functional derivative thereof, and comprising at least one component B consisting of a VL region and a VH region linked directly to each other with a linker sequence L which has a length of <12 amino acids. Furthermore, the present invention also relates to nucleic acids encoding such polypeptides and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: November 21, 2017
    Assignee: UNIVERSITAT STUTTGART
    Inventors: Klaus Pfizenmaier, Roland Kontermann, Martin Siegemund
  • Patent number: 9789204
    Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: October 17, 2017
    Assignee: Immunogen, Inc.
    Inventors: Yong Dai, Yong Wang, Shengjin Jin, Deborah H. Meshulam, Godfrey W. Amphlett
  • Patent number: 9782452
    Abstract: This disclosure demonstrates that blockade of TGF? signaling after a hematopoietic stress (e.g., chemotherapy, transplantation, and infection) accelerates hematopoietic reconstitution and delays the return of cycling hematopoietic stem and progenitor cells (HSPCs) to quiescence. TGF? blockade in these settings promotes multilineage hematopoietic regeneration by prolonging HSPC cycling and by promoting HSC self-renewal, and is useful for treating hematologic deficiencies caused various hematopoietic stresses.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: October 10, 2017
    Assignee: Cornell University
    Inventors: Joseph Scandura, Fabienne Brenet
  • Patent number: 9783604
    Abstract: Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-? (TGF?). TGF?-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGF?1, compared to human TGF?2 and human TGF?3, or may selectively bind human TGF?3, compared to human TGF?1 and human TGF?2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGF?2 and by another co-crystal structure of the scFv version of GC1008 bound to TGF?1.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: October 10, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Ronnie Wei, Aaron Moulin, Magali Mathieu, Clark Pan, Sunghae Park, Huawei Qiu
  • Patent number: 9763868
    Abstract: A problem of the present invention is to provide a skin collagen production-promoting agent without safety problems. Another problem of the present invention is to provide a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product containing such a substance. TGF-? and/or a TGF-? degradation product, which is acquired by degrading TGF-? with a protease such as pepsin, pancreatin, etc., are used as a skin collagen production-promoting agent or the active ingredient of a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product. The aforementioned TGF-? and/or TGF-? degradation product have an effect of increasing the collagen content of the skin.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: September 19, 2017
    Assignee: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Hiroshi Ueno, Yoshikazu Morita, Aiko Ono, Ken Katoh, Noriko Ueda
  • Patent number: 9753041
    Abstract: The present invention provides non-invasive diagnostic methods and kits for determining and/or monitoring oral health and glycemic control in subjects with Type 1 diabetes.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: September 5, 2017
    Assignee: UNIVERISTY OF SOUTH FLORIDA
    Inventors: Amy Christine Alman, Brant Roger Burkhardt
  • Patent number: 9731019
    Abstract: The object of the present invention is novel release systems comprising specific hyaluronic acid amides combined with therapeutically and/or biologically active proteins with a mainly hydrophobic nature, for sustained, slow release over time which increases the efficacy of the medicament and the patient's compliance.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: August 15, 2017
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Monica Campisi, Cristian Guarise, Davide Renier
  • Patent number: 9724388
    Abstract: The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administration every 2 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-administration of a anti-inflammatory drug.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: August 8, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring
  • Patent number: 9718881
    Abstract: The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: August 1, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jesper Gromada, Esther Latres, Andrew Murphy, George Yancopoulos, Lori Morton
  • Patent number: 9718884
    Abstract: Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNF?) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNF? and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: August 1, 2017
    Assignee: Eli Lilly and Company
    Inventors: Rohn L Millican, Jr., Neungseon Seo, Songqing Na, Catherine B. Beidler